SetPoint Medical Launches Innovative Rheumatoid Arthritis Treatment in Texas

In a remarkable advancement for treating chronic autoimmune diseases, SetPoint Medical has successfully launched the first procedure using the SetPoint System in Texas. This groundbreaking procedure was carried out by Dr. Daniel Peterson, a neurosurgeon from Ascension Dell Seton Medical Center at The University of Texas. With this development, SetPoint is expanding its reach and enhancing treatment options for patients suffering from rheumatoid arthritis (RA) in the Southwest.

The SetPoint System is an FDA-approved neuroimmune modulation device designed specifically for adults experiencing moderately to severely active rheumatoid arthritis. As the first of its kind in the United States, this device focuses on stimulating the left vagus nerve to activate anti-inflammatory pathways within the body. For many patients who have exhausted conventional therapies or struggled with severe side effects, this innovative approach may offer new hope for relief and recovery.

Dr. Peterson, who is also a prominent investigator in the RESET-RA study, expressed enthusiasm about the technical sophistication of the SetPoint System. He highlighted how it represents a shift in the landscape of RA treatments, providing a targeted alternative that differs significantly from traditional therapies. The design of the device is specifically engineered for precision engagement with neural pathways, improving patient outcomes.

The first patient to undergo this procedure was referred by Dr. Pendleton B. Wickersham, a certified rheumatologist affiliated with Arthritis Associates in San Antonio. Dr. Wickersham praised the introduction of the SetPoint System, reinforcing its potential to represent a transformative shift in RA treatment paradigms. He emphasized the collaborative effort between surgical partners and rheumatologists in Texas, showcasing a commitment to enhancing care for patients battling this debilitating condition.

SetPoint Medical's recent accomplishments are underscored by the positive results published from the RESET-RA study, appearing in credible medical journals such as Nature Medicine. These studies reveal meaningful improvements in patient well-being and sustained effectiveness over a year of treatment, highlighting the growing momentum of the company's offerings across the country.

CEO Murthy Simhambhatla articulated the significance of this launch as part of a broader mission to expand patient access nationwide. Each new center implementing the SetPoint System contributes to establishing a robust national network of physician partners. This initiative aims to ensure that all individuals living with rheumatoid arthritis have access to this innovative treatment option.

The SetPoint System is targeted at those patients who have encountered inadequate responses or developed intolerances to conventional biological and targeted drug therapies. While it presents an exciting new path for treatment, potential users must be aware of certain precautions as the device should not be used in cases involving prior vagotomy or splenectomy, and safety assessments should be conducted by healthcare providers.

SetPoint Medical remains devoted to improving the standard of care for patients suffering from autoimmune diseases and is exploring the potential of its technology to assist with conditions such as multiple sclerosis and Crohn's disease. As the organization continues its commitment to innovation and patient care, it is set to transform the treatment landscape for many. To learn more about their advancements and patient opportunities, interested individuals can visit their website at setpointmedical.com.

In summary, SetPoint Medical’s recent milestone in Texas marks an important leap forward in the treatment of rheumatoid arthritis, bringing a specialized approach to neuromodulation therapy while highlighting the collaborative efforts among medical professionals to enhance patient solutions across the nation.